Content
Prescription weight loss that puts you first
Side-by-side medication summaries to compare pros and cons, side effects, interactions, and more.
Content
Jardiance
Metformin
Jardiance® (empagliflozin) is an oral medication used to improve blood sugar control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Additionally, Jardiance helps reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. It is also used to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. This medication works as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promoting the excretion of glucose through the urine.
Metformin is an oral medication commonly prescribed to manage blood sugar levels in individuals with type 2 diabetes. It works by decreasing glucose production in the liver, improving the body's sensitivity to insulin, and reducing the amount of sugar absorbed by the intestines. Metformin is often used as a first-line treatment due to its efficacy, safety profile, and additional benefits, such as weight stabilization and low risk of low blood sugar. Common side effects include gastrointestinal issues like nausea, diarrhea, and abdominal discomfort.
Prescription
Prescription
Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Biguinide
Jardiance (empagliflozin) is indicated:
To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure
To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression
To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
Metformin hydrochloride tablets are indicated:
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
Typically taken orally once daily
Comes in 10 mg and 25 mg tablets
Typically taken orally once, twice, or three times daily
Comes in 500 mg, 850 mg, and 1,000 mg tablets
Most common adverse reactions (5% or greater incidence) were:
Urinary tract infections
Female genital fungal infections
For metformin hydrochloride, the most common adverse reactions (>5%) are:
Diarrhea
Nausea/vomiting
Flatulence
Weakness
Indigestion
Abdominal discomfort
Headache
Hypersensitivity to empagliflozin or any of the excipients in Jardiance
See the Full Prescribing Information for information on drug interactions and interference of Jardiance with laboratory tests
Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
Hypersensitivity to metformin
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
Drug interactions: Carbonic anhydrase inhibitors, drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), alcohol
Diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis
Volume depletion
Urosepsis and pyelonephritis
Low blood sugar
Necrotizing fasciitis of the perineum (Fournier's gangrene)
Genital fungal infections
Lower limb amputation
Hypersensitivity reactions
Pregnancy: Potential risk to a fetus especially during the second and third trimesters
Lactation: Not recommended when breastfeeding
Lactic acidosis: See Boxed Warning
Vitamin B12 deficiency: Metformin may lower vitamin B12 levels
Low blood sugar with concomitant use with insulin and insulin secretagogues
Females and males of reproductive potential: Potential for an unintended pregnancy
WARNING: LACTIC ACIDOSIS
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL.
Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information.
If lactic acidosis is suspected, discontinue metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.
*This information is from the label for brand name Jardiance®. See the Full Prescribing Information for more complete information.
*This information is from the metformin hydrochloride label used by Epic Pharma, LLC. See the Full Prescribing Information for more complete information. Metformin is also the active ingredient in brand-name medications, including Glucophage® and Glumetza®, and this information may not be accurate for all medications that include the active ingredient metformin.
The information provided here is NOT MEDICAL ADVICE and is for informational and educational purposes only. The drug comparison tool does not determine eligibility for medications or treatments provided via the Hims/Hers platform. Consultation with a healthcare provider is required to assess suitability for any medical treatment based on individual health and medical history. All product names and associated trademarks are the property of their respective owners.